González EC, Carvajal F, Frómeta A, Arteaga AL, Castells EM, et al. Newborn screening for congenital adrenal hyperplasia in Cuba: six years of experience. Clin Chim Acta 2013;421: 73–8.PubMedWeb of ScienceCrossrefGoogle Scholar
Olgemöller B, Roscher AA, Liebl B, Fingerhut R. Screening for congenital adrenal hyperplasia: adjustment of 17-hydroxyprogesterone cut-off values to both age and birth weight markedly improves the predictive value. J Clin Endocrinol Metab 2003;88:5790–4.CrossrefPubMedGoogle Scholar
Allen DB, Hoffman GL, Fitzpatrick P, Laessig R, Maby S, et al. Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogesterone levels. J Pediatr 1997;130:128–33.PubMedCrossrefGoogle Scholar
van der Kamp HJ, Oudshoorn CG, Elvers BH, van Baarle M, Otten BJ, et al. Cutoff levels of 17-alpha-hydroxyprogesterone in neonatal screening for congenital adrenal hyperplasia should be based on gestational age rather than on birth weight. J Clin Endocrinol Metab 2005;90:3904–7.CrossrefPubMedGoogle Scholar
Hayashi G, Faure C, Brondi MF, Vallejos C, Soares D, et al. Weight-adjusted neonatal 17OH-progesterone cutoff concentrations improve the efficiency of newborn screening for congenital adrenal hyperplasia. Arq Bras Endocrinol Metabol 2011;55: 632–7.CrossrefGoogle Scholar
Zhang Q, Wang B, Chen Y, Jiang D, Chen Y. Multicenter investigation on the impact of newborn infants’ gestational age and birth weight on the level of 17α-hydroxyprogesterone. Zhonghua Er Ke Za Zhi 2014;52:706–9.PubMedGoogle Scholar
Gruñeiro-Papendieck L, Prieto L, Chiesa A, Bengolea S, Bossi G, et al. Neonatal screening program for congenital adrenal hyperplasia: adjustments to the recall protocol. Horm Res 2001;55:271–7.PubMedGoogle Scholar
Fingerhut R, Torresani T. Evaluation of the genetic screening processor (GSPTM) for newborn screening. Anal Methods 2013;18:4769–76.Google Scholar
Wang BJ, Chen YP, Ma J. Validation of GSPTM in 17α-OH-progesterone measurement and establishment of the newborn cut-off value in Suzhou city. J Chin Birth Health Hered 2017;26:78–80.Google Scholar
Hayashi GY, Carvalho DF, de Miranda MC, Faure C, Vallejos C, et al. Neonatal 17-hydroxyprogesterone levels adjusted according to age at sampling and birthweight improve the efficacy of congenital adrenal hyperplasia newborn screening. Clin Endocrinol (Oxf) 2017;86:480–7.CrossrefGoogle Scholar
Mendoza-Rojas VC, Díaz-Martínez LA, Mantilla-Mora G, Contreras-García GA, Mora-Bautista VM, et al. 17-Hydroxiprogesterone values in healthy preterm infants. Colomb Med (Cali) 2017;48:161–6.PubMedGoogle Scholar
Al-Nuaim AR, Abdullah MA, Stevens B, Zain M. Effect of gender, birth weight and gestational age on serum 17-hydroxyprogesterone concentration and distribution among neonates in Saudi Arabia. Indian J Pediatr 1995;62:605–9.PubMedCrossrefGoogle Scholar
Ryckman KK, Cook DE, Berberich SL, Shchelochkov OA, Berends SK, et al. Replication of clinical associations with 17-hydroxyprogesterone in preterm newborns. J Pediatr Endocrinol Metab 2012;25:301–5.PubMedWeb of ScienceGoogle Scholar
Pauwels G, Allegaert K, Régal L, Meulemans A. Risk factors for elevated levels of 17-hydroxyprogesterone during neonatal intensive care unit admission. Acta Clin Belg 2012;67:88–93.PubMedWeb of ScienceGoogle Scholar
Tsuji A, Konishi K, Hasegawa S, Anazawa A, Onishi T, et al. Newborn screening for congenital adrenal hyperplasia in Tokyo, Japan from 1989 to 2013: a retrospective population-based study. BMC Pediatr 2015;15:209.PubMedCrossrefWeb of ScienceGoogle Scholar
Heather NL, Seneviratne SN, Webster D, Derraik JG, Jefferies C, et al. Newborn screening for congenital adrenal hyperplasia in New Zealand, 1994–2013. J Clin Endocrinol Metab 2015;100:1002–8.Web of ScienceCrossrefPubMedGoogle Scholar
About the article
Published Online: 2019-10-11
Published in Print: 2019-11-26
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and have approved its submission.
Research funding: This work was supported by the Guangdong Medical Research Foundation, Funder Id: http://dx.doi.org/10.13039/501100003785 [Grant No.: C201835].
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; the collection, analysis, and interpretation of data; the writing of the report; or the decision to submit the report for publication.